Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00480
|
|||||
| Drug Name |
Cyclacillin
|
|||||
| Synonyms |
(1-Aminocyclohexyl)penicillin; (2S,5R,6R)-6-[(1-aminocyclohexanecarbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(1-aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-(8CI); 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-(1-Aminocyclohexanecarboxamido)penicillanic acid; 6-(1-Aminocyclohexylcarboxamido)penicillanic acid; 6beta-(1-aminocyclohexanecarboxamido)-2,2-dimethylpenam-3alpha-carboxylic acid; AC 98; Aminocyclohexyl penicillin; Aminocyclohexylpenicillin; Bastcillin; C-12104; Calthor; Ciclacilina; Ciclacilina [INN-Spanish]; Ciclacillin; Ciclacillin (JP15/INN); Ciclacilline; Ciclacilline [INN-French]; Ciclacillinum; Ciclacillinum [INN-Latin]; Ciclacillum; Citosarin; Cyclacillin (USAN); Cyclacillin [USAN]; Cyclapen; Cyclapen (TN); Cyclapen-W; Cyclapen-W (TN); Noblicil; Orfilina; Peamezin; Syngacillin; Ultracillin; Vastcillin; Vastcillin (TN); Vipicil; WY 4508; WY4508; Wy-4508; Wyvital
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H23N3O4S
|
|||||
| Canonical SMILES |
CC1(C(N2C(S1)C(C2=O)NC(=O)C3(CCCCC3)N)C(=O)O)C
|
|||||
| InChI |
InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1
|
|||||
| InChIKey |
HGBLNBBNRORJKI-WCABBAIRSA-N
|
|||||
| CAS Number |
CAS 3485-14-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 341.4 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
1.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103770339
,103914475
,104346698
,11112536
,11446317
,11467148
,11468268
,11486856
,124766183
,128055795
,134224408
,134338404
,134985468
,136357160
,137012596
,137178974
,144204085
,15075673
,160964336
,162516292
,178101519
,179149343
,198937842
,226420447
,29286625
,396250
,46508073
,47291276
,47365368
,47440419
,48259416
,48415821
,49699306
,49956857
,50123946
,57269579
,57330251
,583155
,602914
,74457515
,7848397
,8139302
,8164183
,85788579
,92126086
|
|||||
| ChEBI ID |
ChEBI:31444
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | ||
| References | ||||||
| 1 | Cyclacillin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.